/ /

Ophthalmology Times Staff Reports
Ophthalmology included in U.S. News rankings
U.S. News & World Report has released its annual Best Hospitals rankings for 2013-2014. Rounding out the top three ophthalmology hospitals in the United States are: Bascom Palmer Eye Institute; Wills Eye Hospital; and Wilmer Eye Institute.
InSite Vision receives patent for DuraSite 2
InSite Vision Inc. has received a Notice of Allowance from the U.S. Patent and Trademark Office for its next-generation, enhanced drug-delivery system (DuraSite 2) that provides a broad platform for developing topically delivered ocular drugs.
Retina Implant AG’s Alpha IMS gets CE Mark
Retina Implant AG, a developer of subretinal implants for patients blinded by retinitis pigmentosa (RP), has received the CE Mark for its wireless subretinal implant technology (Alpha IMS).
Glaucoma Foundation shifts focus to exfoliation syndrome
Since its founding by world-renown glaucoma specialist Robert Ritch, MD, in 1984, The Glaucoma Foundation has been funding groundbreaking glaucoma research, primarily in the areas of neuroprotection and genetics. Now, the foundation has sharpened its focus to finding a cure for exfoliation syndrome, the leading identifiable cause of open-angle glaucoma worldwide and the most important cause of complications during routine cataract surgery.
TearLab, Sjögren’s Foundation partner for dry eye awareness
TearLab is partnering with the Sjögren’s Foundation to promote “Dry Eye Disease Awareness Month” this year. Throughout July, TearLab will raise awareness through professional communications and in-clinic materials delivered directly to customers.
MVRF awards $1.2 million to retinal research grantees
The Macula Vision Research Foundation (MVRF) has announced its 2013-2014 grant recipients.
Visian ICL with CentraFLOW approved in Korea, Argentina
STAAR Surgical Co. has received regulatory approvals to market its Visian Implantable Collamer Lens (ICL) with CentraFLOW technology from the KFDA in Korea and the ANMAT in Argentina.
iCo completes phase II iDEAL DME study enrollment
iCo Therapeutics Inc. announced it has completed enrollment of its phase II iDEAL Study, which will evaluate the efficacy and safety after repeated injections of iCo-007 in patients with diabetic macular edema (DME).
PBA launches 2013 Most Beautiful Eyes Contest
Prevent Blindness America (PBA) officially has launched its “3rd Annual Most Beautiful Eyes Contest.” The contest allows children across the United States the chance to win a $10,000 educational scholarship.
Perrigo buys ophthalmic portfolio of Fera Pharmaceuticals
Perrigo Co. has acquired the ophthalmic portfolio of Fera Pharmaceuticals, a Long Island, NY-based specialty pharmaceutical company, for an upfront payment of $93 million.


View Results